Key Highlights

  • Cynata has increased its proposed Placement to approximately 75 million shares at A$0.01, raising about A$750,000 before costs, subject to Shareholder approval.
  • If approved, total Capital raised under the placement and the recent entitlement offer would be about A$1.663 million before costs.
  • All material costs relating to recent Cymerus Clinical Trials and terminated agreements have been paid, according to the company.
  • The externally funded NEREID trial of CYP-001 is ongoing, with the second cohort’s follow-up being completed before a DSMB review.

Cynata Therapeutics Limited (ASX:CYP) has provided an update on its proposed placement and corporate activities. The Melbourne-based company has increased the size of the placement, which it expects to raise about A$750,000 before costs, subject to approval at a general meeting expected in January 2027. The announcement also covers the company’s Cymerus platform, its clinical trial activity and its search for new rights.

Placement Size and Terms

The placement was originally announced at about A$550,000 through approximately 55 million placement shares. Caravel Securities has since received firm commitments for an additional A$200,000, bringing the total to about 75 million shares at A$0.01. The Offer Price matches the recently completed entitlement offer, which raised about A$913,000 before costs. None of the additional shares will be issued to related parties.

Each placement share carries one free attaching option for every three shares issued, with an exercise price of $0.02 and an expiry date of 3 May 2029. Caravel Securities will act as lead manager and receive a placement fee of 6% of the amount raised, along with 8.2 million placement fee options. The number of those Options increased from 6 million, reflecting the larger placement size. The company says proceeds will provide greater flexibility to pursue potential transactions to secure rights to new assets, pay placement costs and add Working Capital in line with the replacement prospectus released on 12 October 2026.

Cymerus Platform and Costs

Cynata reports that all material costs relating to its recently completed Cymerus clinical trials, and the termination of employee and service provider agreements, have been paid. The company continues to maintain its Cymerus intellectual property portfolio, including license agreements, patents and cell lines. The Cymerus platform manufactures mesenchymal stromal cells at scale from a single cell source, and the company describes it as genuinely differentiated.

The Board is evaluating options for further development of the Cymerus technology and a number of opportunities to acquire, in-license or otherwise obtain rights to new pharmaceutical or biotechnology assets. The announcement does not specify a preferred route or timeline for either option.

NEREID Trial Progress

The Phase 1/2 NEREID kidney transplant trial of CYP-001 is managed and funded by Leiden University Medical Centre in the Netherlands. Enrolment and treatment of the second cohort are now complete. In the first cohort, three patients each received a single infusion of CYP-001 in addition to standard treatment, and an independent Data and Safety Monitoring Board review found no episodes of kidney transplant rejection and no safety concerns, as announced in December 2025. In the second cohort, three patients each received two infusions.

A DSMB review of the second cohort will take place once the final patient has been followed up for six weeks after the second infusion. Cynata will announce the results once it receives them from the medical centre. CYP-001 is described by the company as an induced pluripotent stem cell-derived mesenchymal stromal cell product candidate for intravenous use.

The placement also reflects the company’s stated need for flexibility while it evaluates its options. Cynata has described the proceeds as intended to support working capital, cover the costs of the placement and provide funds for pursuing potential transactions to secure rights to new assets. The company has confirmed that none of the additional placement shares will be issued to related parties. Shareholders will vote on the placement at a general meeting, and the company has said details of that meeting will be provided in the coming weeks.

Closing Perspective

The placement increase and the company’s cost updates give Cynata additional flexibility while the Board reviews the future of Cymerus and the wider pipeline of potential asset acquisitions. The January 2027 shareholder meeting, the outcome of the second-cohort DSMB review and any transaction involving new Assets are the points at which the company’s direction is likely to become clearer. Until those events, the company’s disclosures describe ongoing evaluation rather than defined development plans.